High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)

Florian Kocher, Arno Amann, Kai Zimmer, Simon Geisler, Dietmar Fuchs, Renate Pichler, Dominik Wolf, Katharina Kurz, Andreas Seeber, Andreas Pircher